A positive fecal immunochemical test (FIT) means a laboratory detected blood in a stool sample; it does not diagnose colorectal cancer. The result starts a diagnostic pathway because FIT cannot show where the bleeding came from.

Someone who receives a positive screening result should contact the program or clinician that ordered the test so follow-up can be arranged. Colonoscopy can inspect the colon directly, remove polyps and take tissue for pathology; another stool sample cannot perform any of those tasks.

Symptoms need assessment rather than routine screening

Screening is designed for people without symptoms. The World Health Organization lists blood in the stool, a change in bowel habits, persistent abdominal pain or bloating, unexplained weight loss, fatigue and iron-deficiency anemia as possible colorectal cancer symptoms.

These signs have many noncancer causes, but they warrant clinical assessment rather than waiting for the next screening invitation. The UK National Health Service advises urgent assessment for black or dark-red stool or bloody diarrhea, and emergency help for nonstop or heavy rectal bleeding, such as large clots or toilet water turning red.

Readers outside the United Kingdom should use local urgent-care or emergency services. A previous negative FIT should not delay assessment when symptoms are present.

A positive result means blood crossed the test cutoff

FIT measures hemoglobin, a blood protein, in a small stool sample. The International Agency for Research on Cancer (IARC) says available FITs have wide ranges of sensitivity and specificity, and that the balance of benefits and harms depends on the cutoff used for a positive result.

A positive result identifies blood, not its source. Australia's national screening program says a positive result does not always mean bowel cancer, that many causes of blood are unrelated to cancer, and that the usual next step is referral for colonoscopy.

The chance of finding cancer cannot be carried from one program to another without context. NHS England reports bowel cancer in seven to 10 of every 100 people who undergo colonoscopy after an abnormal screening result and says its figures are only a general guide, not a personal risk estimate. APPI News did not repeat the source article's 5 percent estimate as a worldwide figure because no international dataset matching that claim was identified.

A fecal immunochemical test collection kit on a bathroom counter (illustrative image)

Colonoscopy completes the positive FIT pathway

IARC found sufficient evidence that screening every two years with FIT, when coupled with colonoscopy after a positive result, reduces colorectal cancer mortality; the reviewed studies reported risk reductions from 10 percent to 40 percent. The evaluation assumes high-quality testing and adequate follow-up, and most of the evidence came from asymptomatic, average-risk populations in middle- or high-income settings.

During colonoscopy, a clinician examines the colon with a camera, can remove polyps and can take a biopsy when tissue needs laboratory testing. These functions allow the procedure to distinguish among findings that a blood test cannot separate.

Colonoscopy also requires bowel cleansing and may involve sedation. England's screening information lists rare risks including a reaction to sedation, heavy bleeding, bowel perforation and a missed lesion; suitability and personal risk depend on health and procedure details.

Because bleeding can be intermittent, a later negative sample cannot by itself resolve an earlier positive result. Australia's program explains that some bowel cancers do not bleed or bleed only sometimes, and directs people with a positive result to seek assessment of the bleeding source.

A clinician explains a colonoscopy report to a patient in a consultation room (illustrative image)

Screening ages and intervals depend on the country

The fifth European Code Against Cancer recommends quantitative FIT every two years for people aged 50 to 74. The US Preventive Services Task Force recommends screening average-risk adults from ages 45 to 75 and lists annual FIT as one option, with selective screening from ages 76 to 85.

Those frameworks apply to specified populations and are not global clinical or coverage rules. Invitation ages, FIT cutoffs, sample procedures, payment and access to follow-up colonoscopy vary by country, so the schedule should come from the program or guideline used where the reader receives care.

The routine interval applies after a negative screening result, not after a positive one. A positive FIT moves the person into a diagnostic pathway even if the next routine invitation would otherwise be one or two years away.

Higher-risk and special populations need a separate plan

The schedules above describe asymptomatic adults at average risk. The World Health Organization identifies family history, inherited syndromes, previous colorectal cancer and certain polyps as risk factors, and says people with a family history or inherited syndrome may need genetic counseling and tailored screening.

The population-screening guidance cited here does not include children and does not establish a single approach during pregnancy. A child or pregnant person with rectal bleeding or a change in bowel habits should receive clinician-led assessment rather than apply an adult home-screening interval; APPI News could not find one international FIT schedule for either group.

Major chronic illness and regular medicines can also affect whether and how colonoscopy is performed. England's program checks health conditions and medicines before colonoscopy and may consider computed tomography colonography when colonoscopy is unsuitable. Any medicine changes should follow instructions from the procedure team.

Positive, negative and inconclusive results lead to different steps

After a positive result, contact the ordering program or clinician and ask how diagnostic follow-up is arranged. If cost, transport, time off work or colonoscopy access creates a barrier, tell the service coordinating the screening rather than treating a second FIT as clearance.

After a negative result, return at the interval set by the local program, but seek assessment if symptoms develop between rounds. An inconclusive result is different: the laboratory could not analyze the sample, so the program may issue a replacement kit and new collection instructions.

Frequently asked questions

Does a positive FIT mean colorectal cancer?
No. It means blood was detected above the test's cutoff, and colonoscopy is used to identify the cause.

Can a second FIT clear a positive result?
No. A later negative result cannot locate the earlier bleeding source, and intermittent bleeding means it cannot rule out colorectal cancer.

Does a negative FIT rule out colorectal cancer?
No. Some cancers do not bleed continuously, and symptoms should be assessed even after a recent negative screening result.

At what age should FIT screening start?
There is no single worldwide starting age or interval. The European and US examples in this guide differ, and local programs may use other eligibility rules.

Should someone with symptoms wait for a screening invitation?
No. Screening schedules are for people without symptoms; blood in stool, persistent bowel changes, unexplained weight loss or lasting abdominal pain warrants clinical assessment.